Review Article

Oreongsan, an herbal medicine prescription developed as a new alternative treatment in patients with chronic subdural hematoma: a narrative review

Seungwon Kwon, Chul Jin, Ki-Ho Cho

Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea

A R T I C L E   I N F O

Article history:
Received 28 September 2018
Received in revised form 13 November 2018
Accepted 20 November 2018
Available online 24 November 2018

Keywords:
Aquaporin-4
Chronic subdural hematoma
Goreisan
Induce diuresis
Oreongsan

A B S T R A C T

Oreongsan (ORS), which is composed of Polyporus, Alismatis Rhizoma, Atractylodis Rhizoma, Poria (Hoe- len), and Cinnamomi Cortex Spissus, has been used as treatment in patients with various symptoms such as thirst, diminished urination, edema, hangover, and diarrhea. ORS is the representative prescription of the 柔軟(isu) effect (translated from Korean as “induce diuresis”), which traditionally means the effect of controlling the water balance. Advancement of modern science has enabled the determination of the action mechanism of herbal medicine complexes. As a result, ORS has been used in the treatment of patients with chronic subdural hematoma (CSDH), representing a novel indication. ORS inhibits the upregulation of aquaporin-4, which is involved in the development of brain edema in the central nervous system. Both aquaporin-1 and aquaporin-4 are expressed in the outer membrane of the CSDH; through its effect as aquaporin-4 inhibitor, ORS prevents the inflow of fluid into the hematoma, thereby preventing the development and recurrence of hematoma. In this study, we reviewed the relationship between the isu effect of ORS and aquaporin, conservative treatment approach in patients with CSDH, and the prevention of recurrence in patients undergoing combined burr hole surgery and treatment with ORS.

© 2019 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

In modern society, traditional medicine using treatment tools that have been used in the past has been used in patients. In the past, traditional East Asian medicine was constructed on the basis of the Yin and Yang. Five-elements philosophy which is one of the ancient recognized systems. In particular, the theory of the use of traditional herbal medicine was constructed on the basis of qi and flavor (氣味). In modern society, pharmacological review of each herb or herbal complex has become possible; as a result, it is possible to determine the specific therapeutic mechanism of traditional herbal medicine, thereby enabling indications of use that were not be previously identified through combined biomedical information for each disease. Oreongsan (ORS), a representative example, is referred to as the representative prescription of the 柔軟(isu) (translated from Korean as “induce diuresis”) effect, which means the

---

* Correspondence author at: Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, 2 KyunHee-daero, Dongdaemun-gu, Seoul 02447, Republic of Korea.
E-mail address: kihocho58@gmail.com (K.-H. Cho).

1 These authors contributed equally to this work as first authors.

---

https://doi.org/10.1016/j.imr.2018.11.003
2213-4220© 2019 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
to traditional East Asian medicine alone which differs from that of the diuretic. Diuretic refers to the effect of in vivo urine production irrespective of the water distribution; whereas, isu refers to adjustment of the imbalance of water distribution in the digestive tract or tissue. An experimental study including mice under conditions of water-deprivation and water-overloading demonstrated the isu effect of ORS. In the water-overloaded model, mice were injected with desmopressin, an anti-diuretic drug, and a large amount of physiological saline (90 mL/kg, i.p.) was injected into the abdominal cavity with complete urination. The water-deprivation models were developed by maintaining the fasting state for 4 hours. In both models, Furosemide administered orally (5 mg/kg) significantly increased the urinary volume to similar level. In contrast, compared to the urinary volume at pretreatment, the administration of ORS showed significant increase of the urinary volume in water-overloaded mice and no change in the urinary volume in water-deprived mice. Thus, the ORS-induced isu effect may be considered as equivalent to the effect of adjusting the water balance by treating the water distribution abnormality unlike the effect of diuretics.

1.2. The relationship between Oreongan and aquaporin-4

The mechanism of the isu effect of ORS is explained through the function of aquaporin (AQP), a water channel. In the past, under common assumption of the kidney as functional target of ORS, studies mainly focused on the kidney. However, ORS has been used as treatment in patients with various systemic diseases such as the diseases of the digestive system, neurological diseases, as well as kidney diseases. Therefore, it was considered to have a systemic effect. Based on this point of view, it is likely that ORS has action on the AQP water channel distributed throughout the body.

AQP is a water-channel protein located in the biomembrane in humans, with a major role in maintaining water homeostasis. AQP has 14 isosforms that are distributed throughout the body with involvement in various biological functions. Reports indicated that AQP-1, 4, and 9 were mainly expressed in the central nervous system in humans; AQP-1 was expressed in the structures of the cerebral nervous system that produce cerebrospinal fluid (CSF) such as the choroidal plexus; indicating its role in the formation of brain edema and increase of water flow through tissue in the presence of brain disease. Moreover, AQP-4 was mainly expressed in the basolateral membranes of ependymal cells and glial cells at the blood–brain and brain–CSF interface, with reported involvement in the movement of water between the blood–brain and brain–CSF, and as the main action mechanism in the development of cytotoxic edema in patients with brain disease. With regard to these functions, ORS is known to inhibit the upregulation of AQP-4 which is known to be involved in the formation of brain edema.

A study evaluating the inhibitory effect of mercury ions, known to inhibit water permeability, and ORS on AQP using oocytes from the African Xenopus, reported that the AQP activity was significantly suppressed in the ORS group, with selective inhibition of the AQP-3, 4, and 5 isosforms, whereas mercury ions inhibited the AQP-1 and 2 isosforms. In particular, Atractylodis Rhizoma as component of ORS was reported to play a role in the inhibition of AQP-4 through the action of its manganese content. Other experimental studies reported that ORS inhibited the upregulation of AQP-4 in the juvenile hypoxic-ischemic encephalopathy model, and the ischemic stroke model, thereby preventing the occurrence of brain edema.

1.3. AQP4 is a factor affecting CSDH development and hematoma expansion

AQP, which plays a major role in the formation of brain edema in patients with brain neurological disease, has recently attracted attention as one of the factors affecting the growth of CSDH. Several studies reported the expression of AQP-1 and AQP-4 in the outer membrane of CSDH; specifically, AQP-1 was expressed in the sinusoid capillaries of the outer membrane of CSDH, and AQP4 in the vascular endothelium of the outer membrane of CSDH. Collectively, both vascular endothelium known as a target area for frequent inflammatory cell invasion, and AQP-4 as the possible main cause of fluid movement to the subdural space have a potential role to contribute to the occurrence of CSDH and hematoma enlargement.

Therefore, the effect of ORS to inhibit upregulation of AQP4 was expected to be involved in the non-surgical treatment effect on the regression of CSDH and preventive effect against postoperative recurrence. ORS-mediated inhibition of AQP-4 located on the outer membrane of CSDH may restrict fluid movement into the subdural hematoma and interfere with the development and expansion of the hematoma. Based on this pharmacological mechanism, the administration of ORS in patients with CSDH became an ongoing treatment mainly in Japan and Korea, with relevant clinical reports.

1.4. CSDH without burr-hole surgery

Burr-hole surgery, the most frequently used treatment for CSDH, showed high effectiveness. However, in patients without symptoms or with mild symptoms, conservative treatments including pharmacotherapy can be attempted. In addition, in the case of lack of consent for surgical treatment of the elderly patients or caregivers, doctors should consider conservative treatments.

Several medications including corticosteroids, tranexamic acid, mannitol, angiotensin converting-enzyme inhibitors, statins and inhibitors of platelet activating factor receptor mediated the resolution of hematoma. However, the efficacy of these medications was not definitive. Therefore, the approach using herbal medicines was suggested, with ORS as representative example. Several reports indicated the effect of conservative treatment using ORS on CSDH. To date, most reports indicated the high effective rate of 80–100%, and duration of medication of 1.8–6.0 months. All reports were case reports or case series. Therefore, the use of ORS in elderly patients who refuse surgical treatments, asymptomatic patients, or patients with mild symptoms is worth considering. However, due to the poor quality of evidence, the conclusion on the effect of ORS as conservative therapy in patients with CSDH cannot be confirmed.

1.5. Inhibitory effect on postoperative recurrence of CSDH

Previous studies indicated that 5–30% of CSDH cases showed recurrence after burr-hole surgery which is standard therapy. Therefore, the prevention of postoperative recurrence is an important issue in the treatment of patients with CSDH.

In a retrospective chart review study, 199 patients with CSDH after burr-hole surgery were identified. The patients were divided into four groups according to the types of medication administered (ORS (n = 48); tranexamic acid (n = 46); combination of ORS and tranexamic acid (n = 35); and control (no additional treatment, n = 70)) and the recurrence rate of CSDH after burr-hole surgery was compared. The recurrence rate by group was 8.3% in the ORS group, 10.9% in the tranexamic acid group, 2.9% in the combination group, and 5.7% in the control group. There was no significant group-wise difference; however, the combination of ORS and tranexamic acid showed the lowest recurrence rate. This result suggested that the combination therapy of ORS and conventional therapy (tranexamic acid) showed the best preventive effect on the recurrence of CSDH after burr-hole surgery. However, in this study, the lack of statistical
significance may have been due to the different number of patients included in each group.

Another retrospective chart review evaluated the recurrent factors and the efficacy of ORS on CSDH after percutaneous subdural tapping performed in 125 patients with unilateral hematoma and measurable initial hematoma pressure. 33 In that study, several risk factors for the recurrence of CSDH including the patients’ age, sex, alcohol consumption, diabetes mellitus, antiplatelet agent or anticoagulant agent administration, history of trauma, severity of neurological deficits, midline shift, hematoma volume, initial hematoma pressure, volume of removed hematoma, and ORS administration were examined. Among 125 patients, 35 (28.0%) showed recurrence. A greater midline shift (p = 0.033) and initial hematoma pressure (p = 0.031) were risk factors that could predict recurrence at post-percutaneous subdural tapping. ORS was prescribed before or after percutaneous subdural tapping in the ORS group, and percutaneous subdural tapping alone was performed in the control group. The rate of recurrence was 27.7% in the ORS group and 29.0% in the control group, without significant difference between the two groups (p = 1.000). Based on these results, ORS was ineffective in preventing recurrence at postoperative period in patients with CSDH. However, the study was conducted using the ORS dose of only 2.5 g, compared with the standardized ORS dose of 7.5 g/day, suggestive of inadequate dose of ORS.

Recently, to overcome the limitations of previous studies, a study evaluated the effect of ORS on re-operation rates after burr-hole surgery in patients with CSDH through analyzing the Japanese inpatient database: 34 the re-operation rate after burr-hole surgery of the ORS group and control group was compared. As a result of primary search, there were 3889 patients in the ORS group and 32,131 patients in the control (ORS non-administration) group. Among these, 3879 pairs were created by one-to-one propensity-score matching which were calculated based on the hospital characteristics (the hospital type, average annual number of CSDH patients

### Table 1
Efficacy of ORS in the Conservative Treatment of Patients with Chronic Subdural Hematoma

| First author [yr] | Number of patients | Patients’ age (average) | Effective cases (%) | Average treatment period (mo) |
|-------------------|--------------------|------------------------|---------------------|-----------------------------|
| Seki (1995) 30     | 8                  | 74                     | 4 (50)              | Unknown                     |
| Onuki (2005) 21    | 1                  | 75                     | 1 (100)             | 6.0                         |
| Muramatu (2005) 32  | 11                 | >80 (88)               | 10 (91)             | 4.6                         |
| Sato (2007) 31     | 1                  | 63                     | 1 (100)             | 1.8                         |
| Miyagami (2009) 24  | 22 (27 with CSDH)  | 50–98 (78)             | 23 (85)             | 2.8                         |
| Yokomizo (2010) 25  | 3                  | 59–82 (74)             | 3 (100)             | 4.0                         |
| Okamoto (2011) 26   | 3                  | 65–92 (74)             | 3 (100)             | 3.2                         |
| Murakami (2012) 27   | 1                  | 73                     | 1 (100)             | 3.0                         |
| Shigemori (2014) 28   | 1                  | 0.75                   | 1 (100)             | 1.6                         |
| Tsutsumi (2014) 29   | 3                  | 60–67 (65)             | 3 (100)             | 4.7                         |
| Mitsuhashi (2015) 30  | 8 (11 with CSDH)  | 64–88 (78)            | 9 (82)              | 2.5                         |
| Total cases        | 70                 | 74                     | 59 (84)             | 3.4                         |

CSDH, chronic subdural hematoma; ORS, Oreongsan.

*Average patients’ age excluding infant’s data.

### Table 2
Efficacy of ORS in the prevention of postoperative recurrence of chronic subdural hematoma

| First author [yr] | Subjects, design, and intervention                                                                 | Results                                                                 |
|-------------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Wakabayashi (2012) 32 | Retrospective chart review 199 patients with CSDH underwent burr-hole surgery | Total recurrence rate: 7% ORS group: 8.3% Tranexamic acid group: 10.9% ORS + tranexamic acid group: 2.9% Control group: 5.7% (no significant difference between the four groups) |
| Okamura (2013) 33   | Retrospective chart review 125 patients with unilateral CSDH underwent percutaneous subdural tapping | Recurrence rate: 27.7% (26/94) in the ORS group vs. 29.0% (9/31) in the control group (p = 1.0) |
| Yasunaga (2015) 34   | Retrospective chart review 7758 patients with CSDH underwent burr-hole surgery within 2d after admission | Re-operation rate: 4.8% in the ORS group vs. 6.2% in the control group (p = 0.001) |
| Goto (2018) 35      | Retrospective chart review 256 patients with CSDH underwent burr-hole surgery | Recurrence rate: 5% in the A group vs. 12% in the Control group (p = 0.046) 6.1% in A + B groups vs. 12% in the Control group (p = 0.082) |
| Katayama (2018) 36   | Retrospective chart review 180 patients with CSDH underwent burr-hole surgery (age, >60 yr-old) | Recurrence rate at 12 weeks: 9.8% (9/92) in the ORS group vs. 12.5% (11/88) in the Control group (no significant difference) |

CSDH, chronic subdural hematoma; ORS, Oreongsan.
treated at each hospital, and admission year) and the patients’ background (the age, sex, body mass index, Barthel index, consciousness level, comorbidities, and the administration of antithrombotics, mannitol, and corticosteroids). The reoperation rate was significantly lower in the ORS group than in the control group (4.8% vs. 6.2%, p = 0.001).

Another retrospective study focused on the role of ORS in the prevention of recurrence of CSDH. The ORS group (early ORS administration after burr-hole surgery), ORS B group (delayed ORS administration in cases with tendency to recur after burr-hole surgery) and control group (absence of treatment after burr-hole surgery). At postoperative day 1, 6, 1 month, and subsequent every month, the recurrence of CSDH was examined using the brain CT image until the absence of visible subdural space; as a result, the recurrence rate was significantly lower in the ORS A group than the control group (5% vs. 12%, p = 0.046).

In a multicenter, prospective, observer blinded, randomized controlled trial, 180 included patients with CSDH at post-burr-hole surgery were randomly assigned to either the ORS group or control (no treatment) group and administered treatment for 12 weeks' period. The recurrence rate after operation was 9.8% in the ORS group and 12.5% in the control group, without significant difference (p = 0.56). Despite the absence of statistical difference, the ratio of recurrence rates between the ORS group and control group was similar to those reported in the previous study. Furthermore, the bilateral CSDH was a significant affecting factor for the recurrence at postoperative period (OR: 3.43, p = 0.02; 95% CI: 1.2–9.8) in the ORS group versus the control group (ORS vs. control: 21.7% (20/92) vs. 12.5% (11/88), p = 0.09). Therefore, a well-designed, large-scale clinical trial should be performed to estimate the efficacy of ORS in preventing postoperative recurrence of CSDH.

We experienced a case of successful prevention of the recurrence of CSDH using ORS after the fourth burr-hole surgery. An 84-year-old man with previous three burr-hole surgeries and recurrences, underwent treatment using ORS to prevent the fourth recurrence. After the fourth surgery and 79 days’ treatment with ORS, there were no signs of recurrence, and the brain CT image was normalized. In addition, there was no recurrence at 1 year 6 months’ follow-up although ORS was not administered. In another case report, ORS was administered for the purpose of preventing CSDH in 10 patients with unruptured intracranial aneurysm who showed increasing subdural fluid collection (SFC) at 2 weeks after clipping and arachnoidplasty; of these, nine patients showed reduced SFC at 1 to 2 months’ treatment duration, which indicated that ORS had the potential to prevent the occurrence of CSDH after burr-hole surgery as well as other surgical approaches of stereotactic craniotomy (Table 2).

1.6. Safety of ORS on treating CSDH

It is known that the administration of ORS on CSDH is considerably safe. A retrospective study reported that no side effect of ORS was reported in 164 patients who administered ORS. Other studies did not specifically report adverse events.

2. Conclusion

Traditionally known for its isu effect, ORS has long been used as treatment for a variety of symptoms, including vomiting, diarrhea, headache, and edema. The effects of ORS are possibly mediated through the water channel, AQP. Based on this pharmacological mechanism, ORS has recently been applied for the conservative treatment of CSDH, and in the prevention of the recurrence of CSDH at post-burr-hole surgery, with ongoing related reports in the literature. In this report, we performed the literature review on the effect of ORS on CSDH. Evidence to date indicated that ORS could be used as an alternative and conservative therapy for the purpose of preventing postoperative recurrence of symptomatic CSDH after burr-hole surgery, and in treating the cases of asymptomatic or mild-symptomatic CSDH. However, most published studies as a case report or retrospective chart review did not provide high-level evidence. Therefore, it is necessary to perform prospective clinical trials with higher quality and evidence level.

3. Clinical recommendation

ORS could be used to prevent the recurrence of CSDH following burr hole surgery. It is recommended to prescribe 2.5–3.0 g of ORS extract, 2–3 times a day. In this case, it is advisable to evaluate the effect of ORS after an administration period of about 3 weeks. ORS could be also used as a conservative treatment even in patients who are very elderly or who refuse surgery.

Funding source

There is no financial support in this study.

Conflicts of interest

All authors declare that there is no conflict of interest.

Acknowledgement

There is no financial support in this study.

References

1. Fung FY, Linn YC. Developing traditional Chinese medicine in the era of evidence-based medicine: current evidences and challenges. Evid Based Complement Alternat Med 2015;2015:425037.
2. Chen H, Guo J, Pang B, Zhao L, Tong X. Application of herbal medicines with bitter flavor and cold property on treating diabetes mellitus. Evid Based Complement Alternat Med 2015;2015:529491.
3. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural product. Molecules 2016;21:E559.
4. Arumugam S, Watanabe K. Japanese Kampo medicines for the treatment of common diseases. 1st ed. USA: Academic Press; 2017:182.
5. Yasunaga H. Effect of Japanese herbal Kampo medicine Gorieisan on reoperation rates after burr-hole surgery for chronic subdural hematoma: analysis of a national inpatient database. Evid Based Complement Alternat Med 2015:2015:817616.
6. Kume K, Kauriya Y, Ozaki M. Effect of Gorieisan, a traditional Japanese Kampo medicine, on postoperative nausea and vomiting in gynecological patients. JA Clin 2017;3:52.
7. Ohnishi N, Nagasawa K, Yokohama T. The verification of regulatory effects of Kampo formulations on body fluid using model mice. J Trad Med 2000;17:131–6.
8. Agre P. The aquaporin water channels. Proc Am Thorac Soc 2006;3:5–13.
9. Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013;14:263–77.
10. Zelenina M. Regulation of brain aquaporins. Neurochem Int 2010;57:468–88.
11. Basaldella L, Perin A, Orvieto E, Marton E, Iškrovich D, Del Tos AP, et al. A preliminary study of aquaporin 1 immunolocalization in chronic subdural hematoma membranes. J Clin Neurosci 2010;17:905–7.
12. Kurita T, Nakamura K, Tabuchi M, Orita M, Ooshima K, Higashino H. Effects of Gorieisan: a traditional Japanese Kampo medicine, on aquaporin 1, 2, 3, 4 and V2R mRNA expression in rat kidney and forebrain. J Med Sci 2011;11:30–4.
13. Nielsen S, Nagelhus EA, Amirny-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in gial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997;17:171–80.
14. Manley GT, Binder DK, Papadopoulos MC, Verkman AS. New insights into water transport and edema in the central nervous system from phenotypic analysis of aquaporin-4 null mice. Neuroscience 2004;129:983–91.
15. Isohama Y. Aquaporin modification: a new molecular mechanism to concern pharmacological effects of Gorieisan. YAKUGAKU ZASSHI 2006;126(Suppl 5):70–3.
16. Nagai K, Isohama Y, Koga T, Ashizuka T, Hisatsune A, Miyata T. Effect of herbal extracts and minerals on aquaporin-mediated water transport across plasma membrane. J Pharmacol Sci 2005;97:103.
